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Antibody-based fusion proteins are the next generation of antibody therapies for cancer and other diseases. CD20 antigen, 
which is overexpressed on cell membranes in nearly 95% of cases of B-cell Non-Hodgkin’s Lymphoma, is an attractive target 
for the therapy of B-lymphoid malignancies. Lidamycin (LDM) is a potent enediyne-containing antitumor antibiotic that now 
has entered phase II clinical trials. In this study, we prepared an engineered fusion protein, scFv-LDP, consisting of an 
anti-CD20 scFv fragment and the apoprotein LDP of LDM using DNA recombination. After purification and refolding, 
scFv-LDP was found to bind specifically to CD20-positive lymphoma cells using ELISA and indirect immunofluorescent cy-
tochemical staining assays. The energized fusion protein scFv-LDP-AE was obtained using molecular reconstitution of the ac-
tive chromophore AE of LDM and scFv-LDP. MTT assay revealed potent cytotoxicity of scFv-LDP-AE to CD20-positive Raji 
and Daudi cells, with IC50 values of 1.21×10
−11 and 6.24×10−11 mol L−1, respectively. An in vivo subcutaneous xenograft model 
of CD20-positive B cell lymphoma in BALB/c (nu/nu) mice was also utilized. Drugs were given intravenously on day 14 and 
21 after tumor transplantation. In terms of maximal tolerated doses, scFv-LDP-AE at 0.3 mg kg−1 suppressed tumor growth by 
79.3%, and LDM at 0.05 mg kg−1 by 68.6% (P<0.05). Results suggested scFv-LDP-AE could be a potential candidate for tu-
mor-targeting therapy. 
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Non-Hodgkin’s Lymphoma (NHL) is a group of malignant 
diseases originating from the lymphatic system [1], and is 
the fifth most common malignancy in the world. Although 
conventional chemotherapy and radiotherapy with NHL 
treatment is effective, these treatment methods may also kill 
some normal cells because of their low selectivity, leading 
to obvious side effects. Therefore targeting therapy is be-
coming more and more important for increasing the effec-
tiveness of cancer treatment. Most NHL originates from B 
lymphocytes, and CD20 antigen is overexpressed on the 
surface of over 95% of NHL cells. CD20 is expressed on 
pre-B cells, immature B cells, mature B cells, and resting 
activated B cells, but is absent from plasma cells, pluripo-
tent stem cells, and other cell types. By contrast, almost no 
free CD20 is found in serum. Therefore, CD20 is an ideal 
target antigen for monoclonal antibody therapy in B-cell 
NHL [2]. The US FDA has approved three monoclonal an-
tibodies against CD20 on lymphoma cells, including Ri-
tuximab, Zevalin and Bexxar [3–5]. In fact the worldwide 
sales of Ribuximab were approximately $5.6 billion in 2009. 
Recently anti-CD20 antibodies have attracted wide attention 
because of their new therapeutic uses in a variety of auto-
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immune diseases [6] (e.g. rheumatoid arthritis [7], systemic 
lupus erythematosus [8,9] and pemphigus [10]). HI47 
(IgG3), a murine monoclonal antibody against CD20, was 
developed by the Institute of Hematology, Chinese Acad-
emy of Medical Sciences in 1990, and was used in the pre-
sent study. This antibody was named CD20+X at the 4th 
International Conference on Human Leukocyte Differentia-
tion Antigens [11].  
A single-chain variable fragment (scFv) is a fusion pro-
tein of the variable regions of the heavy (VH) and light 
chains (VL) in immunoglobulins, connected with a flexible 
linker peptide usually composed of (Gly4Ser)3 [12]. With a 
size of approximately 25 kD, scFv has many advantages 
over intact antibodies. scFv has no Fc-receptor binding ac-
tivation, shows better penetration into solid tumors, has 
much lower immunogenicity, and can be produced in pro-
karyotes. These characteristics render scFv an attractive 
alternative to intact antibodies as a targeting drug carrier for 
therapeutic applications.  
Lidamycin (LDM), also called C-1027, is produced by a 
Streptomyces strain isolated from a soil sample collected in 
China. As a member of the enediyne-containing antitumor 
antibiotics family, LDM is one of the most potent antitumor 
macromolecular peptide antibiotics ever reported [13]. In 
terms of IC50 values, the cytotoxicity of LDM was 10000-     
fold more potent than that of doxorubicin [14,15]. LDM 
contains an enediyne chromophore (843 Da), responsible 
for the extremely potent bioactivity, and a noncovalently 
bound apoprotein LDP (10500 Da), which forms a hydro-
phobic pocket for protecting the chromophore. The apopro-
tein and chromophore can be dissociated and reconstituted, 
and the biological activity of the rebuilt molecule is compa-
rable to that of natural LDM [16–18]. In vivo experiments 
demonstrated the marked growth inhibition LDM exerted 
on different transplantable tumors in mice [19–21]. LDM 
can cause site-specific cleavage of DNA, induce apoptosis 
in cancer cells, and inhibit tumor metastasis as well as an-
giogenesis. All of these responses showed that LDM could 
serve as a promising ‘warhead’ compound for preparing 
antibody-based therapeutics [22]. LDM has now entered 
phase II clinical trials.  
 In the present study we utilized the properties of LDM, 
which can be dissociated and reconstituted, to prepare an 
antibody-based fusion protein, anti-CD20 scFv-LDP-AE. 
Within this fusion protein, the scFv of antibody HI47 served 
as a vehicle and LDM as a “warhead”. The antitumor ef-
fects of scFv-LDP-AE were subsequently studied. 
1  Materials and methods 
1.1  Materials 
1.1.1  Plasmids and strains 
Both E. coli 16C9 and the expression vector pAYZ-scFv 
carrying the gene for the scFv (anti-CD20) were separately 
preserved and constructed in the Institute of Hematology, 
CAMS & PUMC (Tianjin, China). The PGEM-T-LDP vec-
tor carrying the gene for apoprotein LDP of LDM was con-
structed in our laboratory. The pMD 18-T vector and E. coli 
DH5α were purchased from Takara (Dalian, China) and 
BioDev-Tech (Beijing, China), respectively. 
1.1.2  Cells 
The B-cell lymphoma line, Raji and Daudi cells, were cul-
tured in RPMI-1640 supplemented with 10% fetal calf se-
rum at 37°C in a humidified 5% CO2 atmosphere. 
1.1.3  Drugs and reagents 
Restriction endonucleases and T4 DNA ligases were pur-
chased from Takara (Dalian, China); mouse anti-His-Tag 
antibody were from Novagen (Darmstadt, Germany); 
FITC-labeled goat anti-mouse IgG was from Zhongshan 
Golden Bridge Biotechnology (Beijing, China); horseradish 
peroxidase-conjugated goat anti-mouse IgG and chemilu-
minescence detection reagent were from Santa Cruz (Cali-
fornia, USA); PVDF membranes, Centriplus YM or Ultra-
free-MC filter units were from Millipore (USA); Ni-NTA 
resin affinity chromatography column and Sephadex G-25 
column (PD-10) were from Pharmacia (USA); ampicillin, 
bacto-yeast extract and bacto-tryptone were from Oxoid 
(Cambridge, UK); bacto-agar was from Difco (Beijing, 
China); agarose was from Promega (Madison, USA); MTT 
was from Sigma and low molecular standard protein was 
from Takara (Dalian, China). 
1.1.4  Animals 
5–6 week-old BALB/c female nude mice (nu/nu), weighing 
16–18 g, were obtained from the Vital River Laboratories 
(Beijing, China). 
1.2  Methods 
1.2.1  Construction of expression vector pA-scfv-ldp 
The scFv-gene-encoding fragment was cloned by poly-
merase chain reaction from the pAYZ-scfv plasmid DNA 
using direct primer p1(5′-CAGCATATGAACGCGTAC- 
GCTCAGGTGAAG-3′) and reverse primer p2 (5′-CGCGA- 
ATTCTGAACCGCCTCCACCTTTGATCTCCACCTTG-  
GT-3′). The obtained scFv PCR products using Nde I, Mlu I 
and EcoR I sites were cloned into the 18-T vector, yielding 
plasmid 18T-scfv. The recombinant 18T-scfv was digested 
with Nde I/EcoR I, and the released 760 bp scfv gene frag-
ment was subcloned into the pGEMT-LDP plasmid and 
digested with Nde I/EcoR I, creating plasmid pGEMT-scfv- 
ldp. Then the pGEMT-scfv-ldp vector was digested with 
Mlu I/Xho I and the released 1100 bp scfv-ldp fragment was 
ligated to pAYZ, generating recombinant expression plas-
mid pAYZ-scfv-ldp. The inserted DNA fragment was con-
firmed using DNA sequencing. 
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1.2.2  Expression of fusion protein anti-CD20 scFv-LDP 
and Western blot analysis 
E. coli strain 16C9 transformed with pAYZ-scfv-ldp was 
cultured in 2×YT medium (bacto-yeast extract 10 g L−1, 
bacto-tryptone 16 g L−1, NaCl 5 g L−1, ampicillin 50 μg 
mL−1) at 37°C overnight, whereupon the fermentation broth 
was centrifuged to collect the bacterial cells. The fusion 
protein scFv-LDP was induced by resuspending the bacteria 
in AP5 medium (containing 50 μg mL−1 ampicillin) and 
incubating, with gentle shaking, for 24 h at 30°C. After in-
duction, four fractions, including medium, periplasmic, 
soluble cytoplasmic and insoluble samples, were obtained 
for SDS-PAGE analysis and Western blot detection. For 
Western blotting, PVDF membranes containing transferred 
proteins were incubated with a 1:2000 dilution of anti-His-     
Tag monoclonal antibody for 4–5 h, and the bound antibody 
was detected using a 1:1500 dilution of goat anti-mouse 
IgG antibody conjugated with horseradish peroxidase and 
powerful chemiluminescence detection reagents. 
1.2.3  Purification and refolding of fusion protein anti- 
CD20 scFv-LDP 
The bacterial cell pellets were resuspended in binding buffer 
(5 mmol L−1 immidazole, 0.5 mol L−1 NaCl and 20 mmol L−1 
Tris-HCl, pH 7.9), sonicated and the cell lysate centrifuged. 
This step was then repeated. The resulting pellet was resus-
pended and incubated in binding buffer containing 6 mol L−1 
urea for 1 h. Insoluble material was then removed by cen-
trifugation at 16000 g for 30 min. The supernatant was fil-
tered through a 0.45 μm membrane, and then purified by 
Ni-NTA resin affinity chromatography column. The resulting 
purified protein was refolded using stepwise dialysis. Spe-
cifically, the anti-CD20 scFv-LDP fusion protein was diluted 
to 5 μmol L−1 with binding buffer containing 6 mol L−1 urea, 
and then β-mercaptoethanol was added to a final concentra-
tion of 10 mmol L−1. After incubation at room temperature 
for 30 min, the sample was dialyzed against refolding buffer 
(50 mmol L−1 Tris-HCl pH 8.0, 1 mmol L−1 EDTA, 200 
mmol L−1 NaCl, 6 mol L−1 urea) to remove the β-merca- 
ptoethanol. Dialysis was then subsequently performed 
against the same buffer with step-wise reduction in the urea 
concentration (3, 2, 1, 0.5, and 0 mol L−1). At the 1-mol L−1 
dialysis, 750 μmol L−1 of glutathione and 400 μmol L−1 of 
L-arginine were added to the dialysis buffer. The sample 
was then dialyzed against PBS solution (pH 7.4). After cen-
trifugation at 10000 g for 30 min at 4°C, the supernatant 
was collected. The protein was condensed by centrifugation 
at 12000−14000 g and the concentration was determined 
using a BCA protein assay kit from Pierce.  
1.2.4  Enzyme-linked immunosorbent assays (ELISA) 
96-well plates were coated with 0.01% polylysine (200 μL 
well−1) at 4°C overnight and then washed with PBS. Raji or 
Daudi cells were grown in 96-well plates, washed with PBS 
and fixed for 15 min with 0.05% glutaraldehyde/PBS at 4°C. 
Plates were then washed with PBS, and nonspecific binding 
was blocked by incubation with 1% BSA/PBS at 4°C over-
night. The wells were emptied and washed, 50 μL well−1 of 
anti-CD20 scFv-LDP was added in two fold serial dilutions 
at concentrations ranging from 7.50 to 0.06 μmol L−1 and 
were allowed to stand for 2 h at 37°C. After removing the 
unbound scFv-LDP, 50 μL well−1 of 1500-fold diluted 
mouse anti-His-Tag mAb was used as a primary antibody. 
Following incubation and washing, 50 μL well−1 horserad-
ish peroxidase-conjugated goat anti-mouse IgG, at a dilution 
of 1:2000, was added as a secondary antibody. A total  
100 μL of o-phenylenediamine substrate solution was added 
as the coloring reagent, and the reaction was terminated 
after 10 min by the addition of 50 μL of 2 mol L−1 H2SO4. 
Absorbance was measured at 492 nm using a microplate 
reader. 
1.2.5  Indirect immunofluorescent cytochemical staining 
1×106 Raji cells were resuspended in 30 μL PBS containing 
20 μg scFv-LDP and incubated at 4°C for 1 h. The super-
natant was removed by centrifugation at 2000 g for 10 min 
at 4°C. After being washed with PBS, the cells were resus-
pended in PBS solution containing 1500-fold diluted 
anti-His-Tag mAb and incubated at 4°C for 1 h. The super-
natant was discarded by centrifugation at 2000 g for 10 min 
at 4°C. The cells were resuspended in 30 μL working solu-
tion containing FITC-conjugated goat anti-mouse IgG and 
incubated at 4°C for 30 min. The supernatant was removed 
and the cells were fixed in 4% polyformaldehyde. The 
binding of anti-CD20 scFv-LDP to Raji cells was detected 
by FACS analysis. 
1.2.6  Preparation of energized fusion protein scFv-LDP-AE 
10 mg of LDM with high potent activity was suspended in  
5 mL methanol and whisked for 5 min at 4°C. The mixture 
was then placed at −20°C for 1 h. Hence, active enediyne 
(AE) in the supernatant of the reaction mixture was ob-
tained by centrifugation at 16000 g for 20 min at 4°C. The 
above procedure was repeated again to isolate AE com-
pletely. To obtain energized fusion protein scFv-LDP-AE, 
AE in methanol was added to scFv-LDP/PBS (10 mmol L−1, 
pH 7.0) with the molecular ratio of 5:1 and the volume ratio 
of 1:50. The mixture was then placed at room temperature 
for 12 h. Purified scFv-LDP-AE was finally separated from 
free AE using a PD-10 column. 
1.2.7  MTT assays 
CD20-positive Raji or Daudi cells were seeded at 10000 
cells well−1 in 96-well plates, and incubated at 37°C in a 
humidified 5% CO2 incubator overnight. Different concen-
trations of LDM and scFv-LDP-AE were then added and 
incubated for an additional 72 h. 50 μL of MTT (2 mg mL−1 
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in serum-free RPMI 1640 medium) was added in each well, 
and incubated for 4 h at 37°C. The culture supernatant was 
removed gently, and 150 μL of DMSO was added to each 
well. After shaking at room temperature for 15 min, the 
absorbance was determined using a microplate reader at a 
wavelength of 570 nm. Based on the average absorbance of 
triplicate wells, survival ratio was calculated according to 
the following formula:  
Survival ratio = (Atest−Ablank)/(Acontrol−Ablank)×100%. 
1.2.8  Animal experiments 
Experiments were performed with 5–6 week old female 
nude mice. At first, they were exposed to total body irradia-
tion (400 rad) to further suppress their residual immune 
system and facilitate the establishment of xenografts. On the 
second day, 2×107 Raji cells suspended in 0.2 mL PBS were 
subcutaneously injected into the right flank of the mice. On 
day 14, the tumors reached approximately 100 mm3. Ani-
mals were grouped (n=6) and different doses (0.1, 0.2 and 
0.3 mg kg−1) of scFv-LDP-AE were administered IV, as was 
LDM (0.05 mg kg−1) and scFv-LDP (0.3 mg kg−1). Control 
mice were injected with PBS. On day 21, the drugs being 
tested were readministered. Tumor size was measured every 
3 days and tumor volumes were calculated with the follow-
ing formula: V=0.5a×b2, where a and b are the long and the 
perpendicular short diameters of the tumor, respectively. 
The data are presented as mean±SD. Tumor growth curves 
were plotted and the inhibitory rates of tumor growth were 
calculated according to the tumor volume. Student’s t-test 
was used to determine statistically with significant differences. 
P<0.05 was considered significant. 
2  Results 
2.1  Construction and expression of the anti-CD20 scFv- 
LDP fusion protein 
In order to create the anti-CD20 scFv-LDP fusion protein, 
the DNA sequence encoding for the scFv fragment of mAb 
HI47 was genetically fused to the LDP gene, which encodes 
for the apoprotein of LDM. Fusion occurred when a five-    
amino-acid linker (GGGGS) between the C-terminus of 
scFv and the N-terminus of LDP was cloned into the Mlu I/ 
Xho I restriction sites of the pAYZ expression vector, lead-
ing to plasmid pAYZ-scfv-ldp (Figure 1A). The scFv-LDP 
fusion gene was under the control of the phoA promoter and 
an (His)6-Tag was introduced at the C-terminus of the con-
structs to facilitate the purification via immobilized 
metal-affinity chromatography. The fusion gene was com-
posed of 1182 bp and encoded for 394 amino acids.  
The plasmid vector pAYZ-scfv-ldp was transformed into 
E. coli 16C9 and the target protein was induced by AP5 
culture medium. As shown in the Coomassie Blue-stained gel 
in Figure 1B, recombinant proteins accumulated in intracellu- 
 
Figure 1  Construction, expression, and purification of the fusion protein, 
anti-CD20 scFv-LDP. A, Construction of the plasmid pAYZ-scfv-ldp car-
rying the gene for the fusion protein, scFv-LDP. B, SDS-PAGE (left) and 
western-blot (right) analysis of each fraction of E. coli 16C9 cells express-
ing scFv-LDP fusion proteins. 1: molecular weight marker; 2: total proteins 
of E. coli 16C9 carrying plasmid pAYZ-scfv-ldp after induction; 3: me-
dium sample; 4: periplasmic fraction; 5: cytoplasmic soluble fraction; 6: 
cytoplasmic insoluble fraction. C, Purification of the fusion protein scFv- 
LDP by Ni-NTA affinity chromatography. 1: molecular weight marker; 2: 
total cell protein; 3: sample before Ni2+ column; 4–7: contaminating protein 
not bound to the resin; 8–10: scFv-LDP protein obtained by eluting with  
stripping buffer. 
lar inclusion bodies and composed approximately 30% of 
total cell protein. The proteins were running in good agree-
ment with the theoretical molecular weight of 43 kD for the 
anti-CD20 scFv-LDP fusion protein. The fusion construct 
was further confirmed by Western blot using an anti-His- 
Tag antibody (Figure 1B). 
2.2  Purification and refolding of the anti-CD20 scFv- 
LDP fusion protein 
The fusion protein scFv-LDP was purified with Ni-NTA  
resin under denaturing conditions and target proteins of over  
95% purity were obtained, as shown in Figure 1C. After  
refolding in a stepwise manner (see Materials and methods),  
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20 mg soluble scFv-LDP could be harvested from 1 L fer- 
mentation broth. The protein was further elucidated using  
SDS-PAGE, and only a single band with a molecular weight  
of 43 kD could be discerned, indicating that no degradation  
or aggregation occurred in the process of purification and  
refolding. 
2.3  Binding assays 
To confirm the correct folding and functional binding of the  
fusion protein, the binding ability of anti-CD20 scFv-LDP  
to CD20-positive tumor cells was examined by ELISA. The  
data indicated that scFv-LDP bound to the Raji or Daudi  
cells in a dose-dependent and saturable manner. scFv-LDP  
interacted with Raji and Daudi cells with relative affinities  
of 4×10−7 and 8×10−7 mol L−1, respectively, which is slightly  
lower than that of corresponding scFv (Figure 2A and B).  
Indirect immunofluorescent cytochemical staining and  
FACS analysis also showed that both scFv and scFv-LDP  
could specifically bind to Raji or Daudi cells, and the bind- 
ing activity of scFv was slightly higher than that of scFv- 
LDP (Figure 2C). The results indicated that anti-CD20 scFv- 
LDP retained part of the antigen-binding affinity of the  
parent antibody. 
2.4  Generation of the energized fusion protein anti- 
CD20 scFv-LDP-AE 
By adding AE, the active enediyne chromophore of LDM, to  
anti-CD20 scFv-LDP fusion protein solution in controlled  
conditions, the energized fusion protein scFv-LDP-AE was  
prepared. scFv-LDP-AE was purified from free AE after  
separating on a PD-10 column. We found that the scFv-  
LDP-AE molecules showed strong absorbance at both 343  
and 280 nm, representing the chromophore and protein  
moiety, respectively (Figure 3).  
2.5  Death of lymphoma cells in vitro due to the ener-
gized fusion protein scFv-LDP-AE 
Cytotoxicity of scFv-LDP-AE and LDM to tumor cells was  
determined by MTT assay (Figure 4). Both scFv-LDP-AE  
and LDM displayed extremely potent cytotoxicity to dif- 
ferent tumor cells. The IC50 values of scFv-LDP-AE and  
LDM in CD20-positive Raji cells were 1.21×10−11 and 7.13× 
10−11 mol L−1, respectively, and 6.24×10−11 and 2.91×10−10  
mol L−1 in CD20-positive Daudi cells. The IC50 values of  
scFv-LDP-AE and LDM in CD20-negative MCF7 cells  
were 3.39×10−9 and 5.91×10−10 mol L−1, respectively. The  
results suggested that the scFv-LDP-AE showed greater  
cytotoxicity in CD20-positive lymphoma cells than free  
LDM, which was most likely due to the targeting effects of  
anti-CD20 scFv in the fusion construct. 
2.6  Animal experiments 
Antitumor experiments were performed with subcutaneous  
Raji xenografts established in nude mice. As shown in Fig- 
ure 5, both scFv-LDP-AE and LDM could inhibit or retard  
the growth of Raji xenografts significantly, with scFv-LDP-     
AE inhibiting tumor growth in a dose-dependent manner.  
As evaluated on day 41, scFv-LDP-AE at 0.2 and 0.3  
mg kg−1 suppressed the tumor growth by 70.5% and 79.3%,  
respectively, whereas free LDM at the tolerated dose of  
0.05 mg kg−1 showed an inhibition rate of 68.6%. The inhi-
bition rate of scFv-LDP-AE at 0.3 mg kg−1 demonstrated  
 
 
Figure 2  Immunoreactivity analysis of anti-CD20 scFv and scFv-LDP. A, Immunoreactivity to Raji and Daudi cells by ELISA; B, immunoreactivity to 
Daudi cells by ELISA; C, specific binding to Raji cells by indirect immunofluorescence and FACS analysis. 
260 Fang H, et al.   Sci China Life Sci   March (2011) Vol.54 No.3 
 
 
Figure 3  Separation of the energized fusion protein anti-CD20 scFv- 
LDP-AE from free AE on a PD-10 column (Sephadex G-25; Amersham).  
Elute, 1×PBS. 
 
Figure 4  Growth inhibition effects of scFv-LDP-AE and LDM on Raji 
(A) and Daudi (B) cells determined using MTT assay. 
statistically significant differences (P<0.05) compared with 
that of LDM at 0.05 mg kg−1. Almost no inhibitory effect 
could be achieved in the group treated with fusion protein 
scFv-LDP at 0.3 mg kg−1 compared with the control group. 
All treated mice survived at that time of the study. No se-
vere side-effects were observed during the treatment, which 
implied that the therapeutic efficacy of scFv-LDP-AE at a 
tolerated dose was stronger than that of free LDM. 
 
Figure 5  Energized fusion protein scFv-LDP-AE inhibited the growth of 
Raji xenografts in nude mice. 
3  Discussion 
Since Rituximab (RTX), the CD20-specific chimeric mono-
clonal antibody, was approved by the US FDA in 1997 for 
B cell NHL, markedly improved clinical responses in 
B-lymphoid malignancies have been observed [23]. The 
success of RTX presents clear opportunity for anti-
body-based agents in lymphoma therapy. Unfortunately, 
approximately 50% of patients with aggressive B-cell NHL 
are primary refractory or develop relapses after treatment 
with RTX. The development of Y-90 ibritumomab tiuxetan 
(Zevalin) and I-131 tositumomab (Bexxar), radiolabelled 
antibodies with a different mechanism of action compared 
to RTX, overcame the problem of RTX-resistance. These 
compounds, however, have their own problems, such as a 
low response rate following the second treatment, short dura-
tion of response, a higher risk for secondary tumors, serious 
side effects, and poor tolerance in patients [24,25]. Therefore, 
improvements in this area are still greatly required.  
Engineered fusion proteins, composed of an antibody 
fragment and an effector molecule, represent a new class of 
highly active antibody-based therapeutic that is now being 
developed for immunotherapy of malignant tumors. In this 
study we explored a new antibody-targeting fusion protein 
anti-CD20 scFv-LDP-AE. Anti-CD20 scFv-LDP-AE is 
composed of an anti-CD20 scFv fragment and LDM. The 
scFv moiety plays a crucial role in transferring the LDM to 
the tumor site, and then LDM kills the tumor cells by caus-
ing double strand DNA cleavage [26,27]. The fusion con-
struct, therefore, allows the toxic side effects of LDM in 
normal cells to be avoided. Our results indicate that the en-
gineered and energized fusion protein scFv-LDP-AE not 
only showed potent cytotoxicity to cancer cells, but also 
demonstrated significant antitumor effects during in vivo 
experiments. The fusion protein (0.3 mg kg−1) suppressed 
 Fang H, et al.   Sci China Life Sci   March (2011) Vol.54 No.3 261 
 
the growth of Raji xenografts by 79.3%, which demon-
strated statistically significant differences (P<0.05) com-
pared with that of LDM at the maximal tolerated doses of 
0.05 mg kg−1. This finding suggests that scFv-LDP-AE in-
creases the therapeutic potential of LDM.  
scFv-LDP-AE and Rituximab are antibody-based drugs 
for the same target, CD20, and used in the therapy of B-cell 
NHL. However, the therapeutic effect of RTX depends on 
the host immune effector system, including antibody-de-     
pendent cell-mediated cytotoxicity (ADCC) and comple-
ment-dependent cytotoxicity (CDC). Continuous admini-
stration of RTX and high tumor burden can exhaust host 
effector function and nullify the effect of RTX [28]. The 
radiolabelled antibodies, Zevalin and Bexxar, exert effects 
dependent on β-emissions with path lengths of 1–5 mm, and 
thus avoid the effector exhaustion problem of RTX. 
γ-radiation, however, is a safety concern as they can damage 
nearby progenitor cells in bone marrow, and cause pancy-
topenia. Sublethal radiation damage to bone marrow stem 
cells increases the risk of myelodysplastic syndrome and/or 
acute myelogenous leukemia. Interestingly, anti-CD20 
scFv-LDP-AE elicits cytotoxicity through conjugated LDM 
without any γ-radiation, rather than ADCC or CDC effects, 
and therefore avoids the effector-exhaustion problem, which 
hampered the efficacy of RTX [29]. In addition, the hypoxic 
nature of cells within solid tumors limits the efficacy of 
anticancer therapies, such as ionizing radiation and conven-
tional radiomimetics, because their mechanisms of action 
require oxygen to induce lethal DNA breaks. Terry et al. 
[30] reported that LDM could preferentially target hypoxic 
cells within tumors and overcome the radioresistance asso-
ciated with poorly oxygenated cells. Therefore, anti-CD20 
scFv-LDP-AE has the potential to overcome both the 
RTX-resistance and the radioresistance associated with 
poorly oxygenated cells in the treatment of B-cell NHL. 
Because the LDM molecule can be separated and recon-
stituted, we prepared the engineered and energized fusion 
protein anti-CD20 scFv-LDP-AE consisting of an anti-    
CD20 scFv fragment and LDM using DNA recombination 
and molecular reconstitution. In contrast to traditional 
chemical coupling approaches, which lead to heterogeneous 
products and a complex manufacturing process, our meth-
ods preserve the high-order structure and activity of the 
antibody moiety, and easily obtained the perfect 1:1 anti-
body-effector ratio in the final products. Furthermore, we 
can obtain the target protein simply in E. coli and avoid the 
complex and expensive mammalian cell expression systems 
commonly used for the expression of recombinant antibod-
ies at present time. Therefore, the fusion protein anti-CD20 
scFv-LDP-AE could be the next generation of antibody-    
based drugs offering the potential to overcome RTX-resis-    
tance and radioresistance and may be a promising therapy 
against CD20-positive B-cell lymphoma.  
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